生活方式步行干预对射血分数降低心衰患者的功能能力影响:WATCHFUL试验
WATCHFUL试验为6个月多中心随机对照研究,纳入202例射血分数降低心衰患者,比较结合自我监测与定期电话咨询的步行干预与常规护理。结果显示干预组每日步数增加约25%,但6分钟步行试验距离无组间差异(平均7.4米,95%CI -8.0至22.7,P=0.345)。
要点
- 步行干预未改善6分钟步行试验距离,主要终点阴性。
- 干预组每日步数增加1420步(95%CI 749-2091),中高强度活动增加8.2分钟/日(95%CI 3.0-13.3)。
- 其他次要终点(NT-proBNP、生活质量等)均无组间差异。
核心结论
- 生活方式步行干预改善了每日步数约25%,但未对应改善功能能力。
- 增加体力活动与功能结局之间的缺乏关联需进一步研究。
研究设计与样本
- 6个月多中心平行组随机对照试验,在捷克6个心血管中心招募患者。
- 纳入标准:≥18岁,左心室射血分数<40%,NYHA II或III级症状,指南推荐药物治疗稳定。
- 排除基线6分钟步行试验超过450米者。
- 共筛查218例,随机202例;平均年龄65岁,女性22.8%,NYHA II级90.6%,左心室射血分数中位数32.5%,6分钟步行试验中位数385米。
- 主要分析为意向性治疗。
主要发现
- 6个月时6分钟步行试验距离组间差异无统计学意义:平均7.4米(95%CI -8.0至22.7;P=0.345;n=186)。
- 干预组较对照组每日步数平均增加1420步(95%CI 749至2091)。
- 干预组较对照组每日中高强度活动时间平均增加8.2分钟(95%CI 3.0至13.3)。
- 其他次要结局(NT-proBNP、高敏C反应蛋白、射血分数、人体测量、抑郁评分、自我效能、生活质量、生存风险评分)均未检测到组间差异。
临床怎么用
- 对于稳定射血分数降低心衰患者,可考虑步行干预以增加每日步数和中高强度活动。
- 但步行干预未必能改善6分钟步行试验所评估的功能能力,需设定合理预期。
局限性
- 基线6分钟步行试验超过450米者被排除,结果可能不适用于功能能力较好的患者。
- 干预为6个月,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physical activity is pivotal in managing heart failure with reduced ejection fraction, and walking integrated into daily life is an especially suitable form of physical activity. This study aimed to determine whether a 6-month lifestyle walking intervention combining self-monitoring and regular telephone counseling improves functional capacity assessed by the 6-minute walk test (6MWT) in patients with stable heart failure with reduced ejection fraction compared with usual care. METHODS: The WATCHFUL trial (Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Reduced Ejection Fraction) was a 6-month multicenter, parallel-group randomized controlled trial recruiting patients with heart failure with reduced ejection fraction from 6 cardiovascular centers in the Czech Republic. Eligible participants were ≥18 years of age, had left ventricular ejection fraction <40%, and had New York Heart Association class II or III symptoms on guidelines-recommended medication. Individuals exceeding 450 meters on the baseline 6MWT were excluded. Patients in the intervention group were equipped with a Garmin vívofit activity tracker and received monthly telephone counseling from research nurses who encouraged them to use behavior change techniques such as self-monitoring, goal-setting, and action planning to increase their daily step count. The patients in the control group continued usual care. The primary outcome was the between-group difference in the distance walked during the 6MWT at 6 months. Secondary outcomes included daily step count and minutes of moderate to vigorous physical activity as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity C-reactive protein biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. The primary analysis was conducted by intention to treat. RESULTS: Of 218 screened patients, 202 were randomized (mean age, 65 years; 22.8% female; 90.6% New York Heart Association class II; median left ventricular ejection fraction, 32.5%; median 6MWT, 385 meters; average 5071 steps/day; average 10.9 minutes of moderate to vigorous physical activity per day). At 6 months, no between-group differences were detected in the 6MWT (mean 7.4 meters [95% CI, -8.0 to 22.7]; P=0.345, n=186). The intervention group increased their average daily step count by 1420 (95% CI, 749 to 2091) and daily minutes of moderate to vigorous physical activity by 8.2 (95% CI, 3.0 to 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. CONCLUSIONS: Whereas the lifestyle intervention in patients with heart failure with reduced ejection fraction improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the lack of association between increased physical activity and functional outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03041610.
引用
- Vetrovsky, Siranec, Frybova, et al. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial. Circulation. 2023. PMID: 37955615. doi:10.1161/CIRCULATIONAHA.123.067395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。